Congenital genetic inborn errors of metabolism presenting as an adult or persisting into adulthood: Neuroimaging in the more common or recognizable disorders

Seminars in Ultrasound, CT and MRI

Volumn 35, Issue 2, 2014, Pages 160-191

  Krishna, Shri H ^a,b   McKinney, Alexander M ^a,b   Lucato, Leandro T ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM1; GANGLIOSIDE GM2; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A LYASE; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN 1; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

3 METHYLGLUCATONIC ACIDURIA; ABCD1 GENE; ACIDEMIA; ACIDURIA; ADRENOLEUKODYSTROPHY; AGE DISTRIBUTION; ALEXANDER DISEASE; AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; ARSA GENE; ARTICLE; ATP7B DEFECT; ATP7B GENE; BILATERAL STRIOAPALLIDODENTATE CALCINOSIS; BRAIN CYST; CARBOHYDRATE METABOLISM; CHROMOSOME 18; COCKAYNE SYNDROME; CONGENITAL DISORDER; CONGENITAL GENETIC INBORN ERRORS OF METABOLISM; CYTOSKELETON; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISORDERS OF LIPID METABOLISM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FABRY DISEASE; FAHR DISEASE; FIBROID LEUKODYSTROPHY; FLUID ATTENUATED INVERSION RECOVERY; FRACTIONAL ANISOTROPY; GALC GENE; GANGLIOSIDE METABOLISM DEFECT; GAUCHER DISEASE; GENE; GENETIC ASSOCIATION; GENETIC DISORDER; GLIAL FIBRILLARY ACIDIC PROTEIN DEFECT; GLOBOID CELL LEUKODYSTROPHY; GLOBOSIDE METABOLISM DEFECT; GLUCOCEREBROSIDE METABOLISM DEFECT; GLUTARIC ACIDURIA; GLYCOPROTEINOSIS; HUMAN; HUNTINGTON CHOREA; HYDROXYMETHYLGLUTARYL COENZYME A LYASE DEFICIENCY; HYPOMYELINATION HYPODONTIA HYPOGONADOTROPHIC HYPOGONADISM SYNDROME; IDIOPATHIC BASAL GANGLIA CALCIFICATION; INBORN ERROR OF METABOLISM; LEIGH DISEASE; LEIGHLIKE DISEASE; LIPIDOSIS; LYSOSOME STORAGE DISEASE; MAPLE SYRUP URINE DISEASE; MEGANCEPHALIC LEUKOENCEPHALOPATHY; MELAS SYNDROME; METACHROMATIC LEUKODYSTROPHY; MITOCHONDRIAL DEPLETION SYNDROME; MLC 1 GENE; MUCOPOLYSACCHARIDOSIS; MYCOLONIC EPILEPSY WITH RAGGED RED FIBERS; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROIMAGING; NIEMANN PICK DISEASE; NPC GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONSET AGE; PATHOPHYSIOLOGY; PELIZAEUS MERZBACHER DISEASE; PHENYLKETONURIA; POLYMERASE III GENE; POLYMERASE III RELATED LEUKODYSTROPHY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIMARY FAMILIAL BRAIN CALCIFICATION; PRIORITY JOURNAL; PROPIONIC ACIDEMIA; PROTEINOSIS; PROTEOLIPID PROTEIN 1 RELATED LEUKODYSTROPHY; SEX DIFFERENCE; SIALIC ACID STORAGE DISEASE; SLC17A5 GENE; SPHINGOMYELIN METABOLISM DEFECT; SUBCORTICAL CYST; SYMPTOMATOLOGY; T1 WEIGHTED IMAGING; UREA CYCLE DISORDER; VANISHING WHITE MATTER DISEASE; WILSON DISEASE; ADULT; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; CHRONIC DISEASE; FEMALE; MALE; PATHOLOGY; PROCEDURES;

ADULT; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; CHRONIC DISEASE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING;

EID: 84898684935     PISSN: 08872171     EISSN: 15585034     Source Type: Journal    
DOI: 10.1053/j.sult.2013.10.008     Document Type: Article

References (227)

1. Moser H.W., Moser A.B., Smith K.D., et al. Adrenoleukodystrophy: Phenotypic variability and implications for therapy. J Inherit Metab Dis 1992, 15:645-664.
2. Bezman L., Moser A.B., Raymond G.V., et al. Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001, 49:512-517.
3. Mosser J., Douar A.M., Sarde C.O., et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993, 361:726-730.
4. Loes D.J., Fatemi A., Melhem E.R., et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003, 61:369-374.
5. Kumar A.J., Köhler W., Kruse B. MR findings in adult-onset adrenoleukodystrophy. Am J Neuroradiol 1995, 16:1227-1237.
6. Farina L., Bizzi A., Finocchiaro G. MR imaging and proton MR spectroscopy in adult Krabbe disease. Am J Neuroradiol 2000, 21:1478-1482.
7. Inoue S., Terada S., Matsumoto T., et al. A case of adult-onset adrenoleukodystrophy with frontal lobe dysfunction: A novel point mutation in the ABCD1 gene. Intern Med 2012, 51:1403-1406.
8. Li J., Hsu C., Tsai C. Spinocerebellar variant of adrenoleukodystrophy with a novel ABCD1 gene mutation. J Neurol Sci 2010, 290:163-165.
9. Eichler F.S., Itoh R., Barker P.B., et al. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: Initial experience. Radiology 2002, 225:245-252.
10. Eichler F.S., Barker P.B., Cox C., et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 2002, 58:901-907.
11. Wilken B., Dechent P., Brockmann K. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatrics 2003, 34:237-246.
12. McKinney A.M., Nascene D., Miller W.P., et al. Childhood cerebral X-linked adrenoleukodystrophy: Diffusion tensor imaging measurements for prediction of clinical outcome after hematopoietic stem cell transplantation. Am J Neuroradiol 2013, 34:641-649.
13. Musolino P.L., Rapalino O., Caruso P. Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy. Brain 2012, 135:2676-2683.
14. Fluharty A.L., Arylsulfatase A. Deficiency. 2006 May 30 [Updated 2011 Aug 25]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1130/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
15. Kohler W. Leukodystrophies with late disease onset: An update. Curr Opin Neurol 2010, 23:234-241.
16. Barkovich A.J. Toxic and metabolic disorders. Pediatric Neuroimaging 2005, 76-189. Lippincott Williams and Wilkins, Philadelphia, PA. A.J. Barkovich (Ed.).
17. Bostantjopoulou S., Katsarou Z., Michelakaki H., et al. Seizures as a presenting feature of late onset metachromatic leukodystrophy. Acta Neurol Scand 2000, 102:192-195.
18. Rauschka H., Colsch B., Baumann N., et al. Late-onset metachromatic leukodystrophy: Genotype strongly influences phenotype. Neurology 2006, 67:859-863.
19. Cengiz N., Ozbenli T., Onar M., et al. Adult metachromatic leukodystrophy: Three cases with normal nerve conduction velocities in a family. Acta Neurol Scand 2002, 105:454-457.
20. Sener R.N. Metachromatic leukodystrophy: Diffusion MR imaging findings. Am J Neuroradiol 2002, 23:1424-1426.
21. Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol 2005, 15:2284-2303.
22. Martin A., Sevin C., Lazarus C. Toward a better understanding of brain lesions during metachromatic leukodystrophy evolution. Am J Neuroradiol 2012, 33:1731-1739.
23. Eichler F., Grodd W., Grant E., et al. Metachromatic leukodystrophy: A scoring system for brain MR imaging observations. Am J Neuroradiol 2009, 30:1893-1897.
24. Wenger D.A. Krabbe Disease. 2000 Jun 19 [Updated 2011 Mar 31]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1238/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
25. Duffner P.K., Barczykowski A., Kay D.M., et al. Later onset phenotypes of Krabbe disease: Results of the world-wide registry. Pediatr Neurol 2012, 46:298-306.
26. Henderson R.D., MacMillan J.C., Bradfield J.M. Adult onset Krabbe disease may mimic motor neurone disease. J Clin Neurosci 2003, 10:638-639.
27. Bajaj N.P.S., Waldman A., Orrell R., et al. Familial adult onset of Krabbe's disease resembling hereditary spastic paraplegia with normal neuroimaging. J Neurol Neurosurg Psychiatry 2002, 72:635-638.
28. Wang C., Melberg A., Weis J., et al. The earliest MR imaging and proton MR spectroscopy abnormalities in adult-onset Krabbe disease. Acta Neurol Scand 2007, 116:268-272.
29. Demaerel P., Wilms G., Verdru P., et al. MR findings in globoid cell leukodystrophy. Neuroradiology 1990, 32:520-522.
30. Guo A.C., Petrella J.R., Kurtzberg J., et al. Evaluation of white matter anisotropy in Krabbe disease with diffusion tensor MR imaging: Initial experience. Radiology 2001, 218:809-815.
31. McGraw P., Liang L., Escolar M., et al. Krabbe disease treated with hematopoietic stem cell transplantation: Serial assessment of anisotropy measurements-Initial experience. Radiology 2005, 236:221-230.
32. Escolar M.L., Poe M.D., Smith J.K., et al. Diffusion tensor imaging detects abnormalities in the corticospinal tracts of neonates with infantile Krabbe disease. Am J Neuroradiol 2009, 30:1017-1021.
33. Provenzale J.M., Escolar M., Kurtzberg J. Quantitative analysis of diffusion tensor imaging data in serial assessment of Krabbe disease. Ann N Y Acad Sci 2005, 1064:220-229.
34. Desnick R.J., Ioannou Y.A., Eng C.M. Alpha-galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Diseases 2001, 3733-3774. McGraw-Hill, New York, NY. ed 8. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
35. Eng C.M., Fletcher J., Wilcox W.R., et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007, 30:184-192.
36. Wozniak M.A., Kittner S.J., Tuhrim S., et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010, 41:78-81.
37. Rolfs A., Böttcher T., Zschiesche M., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: A prospective study. Lancet 2005, 366:1794-1796.
38. Buechner S., Moretti M., Burlina A.P., et al. Central nervous system involvement in Anderson-Fabry disease: A clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008, 79:1249-1254.
39. Reisin R.C., Romero C., Marchesoni C., et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci 2011, 305:41-44.
40. Moore D.F., Ye F., Schiffmann R., et al. Increased signal intensity in the pulvinar on T1-weighted images: A pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 2003, 24:1096-1101.
41. Burlina A.P., Manara R., Caillaud C., et al. The pulvinar sign: Frequency and clinical correlations in Fabry disease. J Neurol 2008, 255:738-744.
42. Fellgiebel A., Keller I., Marin D., et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009, 72:63-68.
43. Paavilainen T., Lepomäki V., Saunavaara J., et al. Diffusion tensor imaging and brain volumetry in Fabry disease patients. Neuroradiology 2013, 55:551-558.
44. Gavazzi C., Borsini W., Guerrini L., et al. Subcortical damage and cortical functional changes in men and women with Fabry disease: A multifaceted MR study. Radiology 2006, 241:492-500.
45. Vanier M.T., Millat G. Niemann-Pick disease type C. Clin Genet 2003, 64:269-281.
46. Sevin M., Lesca G., Baumann N., et al. The adult form of Niemann-Pick disease type C. Brain 2007, 130:120-133.
47. Walterfang M., Fahey M., Abel L., et al. Size and shape of the corpus callosum in adult Niemann-Pick type C reflects state and trait illness variables. Am J Neuroradiol 2011, 32:1340-1346.
48. Walterfang M., Fahey M., Desmond P., et al. White and gray matter alterations in adults with Niemann-Pick disease type C: A cross-sectional study. Neurology 2010, 75:49-56.
49. Walterfang M., Patenaude B., Abel L.A., et al. Subcortical volumetric reductions in adult Niemann-Pick disease type C: A cross-sectional study. Am J Neuroradiol 2013, 34:1334-1340.
50. Tedeschi G., Bonavita S., Barton N.W., et al. Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease. J Neurol Neurosurg Psychiatry 1998, 65:72-79.
51. Battisti C., Tarugi P., Dotti M.T., et al. Adult-onset Niemann-Pick type C disease: A clinical, neuroimaging, and molecular genetic study. Mov Disord 2007, 18:1405-1409.
52. Trouard T.P., Heidenreich R.A., Seeger J.F., et al. Diffusion tensor imaging in Niemann-Pick type C disease. Pediatr Neurol 2005, 33:325-330.
53. Zaaraoui W., Crespy L., Rico A., et al. In vivo quantification of brain injury in adult Niemann-Pick disease type C. Mol Genet Metab 2011, 103:138-141.
54. Yoshida K., Oshima A., Sakuraba H., et al. GM1 gangliosidosis in adults: Clinical and molecular analysis of 16 Japanese patients. Ann Neurol 1992, 31:328-332.
55. Uyama E., Terasaki T., Watanabe S., et al. Type 3 GM1 gangliosidosis: Characteristic MRI findings correlated with dystonia. Acta Neurol Scand 1992, 86:609-615.
56. Muthane U., Chickabasaviah Y., Kaneski C., et al. Clinical features of adult GM1gangliosidosis: Report of three Indian patients and review of 40 cases. Mov Disord 2004, 19:1334-1341.
57. Roze E., Paschke E., Lopez N., et al. Dystonia and Parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005, 20:1366-1369.
58. Frey L.C., Ringel S.P., Filley C.M. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol 2005, 62:989-994.
59. Fukumizu M., Yoshikawa H., Takashima S., et al. Tay-Sachs disease: Progression of changes on neuroimaging in four cases. Neuroradiology 1992, 34:483-486.
60. Streifler J.Y., Gornish M., Hadar H., et al. Brain imaging in late-onset GM2 gangliosidosis. Neurology 1993, 43:2055-2058.
61. Inglese M., Nusbaum A.O., Pastores G.M., et al. MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis. Am J Neuroradiol 2005, 26:2037-2042.
62. Zimran A., Gelbart T., Westwood B., et al. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 1991, 49:855-859.
63. Schiffmann R., Heyes M.P., Aerts J.M., et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 1997, 42:613-621.
64. Abdel Razek A.A., Abd El-Gaber N., Abdalla A., et al. Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III. Neuroradiology 2009, 51:773-779.
65. Mercimek-Mahmutoglu S., Gruber S., Rolfs A., et al. Neurological and brain MRS findings in patients with Gaucher disease type 1. Mol Genet Metab 2007, 91:390-395.
66. Davies E.H., Seunarine K.K., Banks T., et al. Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging. J Inherit Metab Dis 2011, 34:549-553.
67. Poorthuis B.J., Wevers R.A., Kleijer W.J., et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999, 105:151-156.
68. Nelson J., Crowhurst J., Carey B., et al. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A 2003, 123A:310-313.
69. Clarke L.A., Heppner J. Mucopolysaccharidosis type I. 2002 Oct 31. [Updated 2011 Jul 21]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1162/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
70. Scarpa M. Mucopolysaccharidosis Type II. 2007 Nov 6 [Updated 2011 Feb 22]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1274/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
71. Ruijter G.J., Valstar M.J., van de Kamp J.M., et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 2008, 93:104-111.
72. Montaño A.M., Tomatsu S., Gottesman G.S., et al. International Morquio A Registry: Clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis 2007, 30:165-174.
73. Zafeiriou D.I., Batzios S.P. Brain and spinal MR imaging findings in mucopolysaccharidoses: A review. Am J Neuroradiol 2013, 34:5-13.
74. Azevedo A.C., Artigalás O., Vedolin L., et al. Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI. J Inherit Metab Dis 2013, 36:357-362.
75. Tanaka A., Okuyama T., Suzuki Y., et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan. Mol Genet Metab 2012, 107:513-520.
76. Adams D., Gahl W.A. Free sialic acid storage disorders. 2003 Jun 13 [Updated 2013 Jun 6]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1470/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
77. Varho T.T., Alajoki L.E., Posti K.M., et al. Phenotypic spectrum of Salla disease, a free sialic acid storage disorder. Pediatr Neurol 2002, 26:267-273.
78. Haataja L., Parkkola R., Sonninen P., et al. Phenotypic variation and magnetic resonance imaging (MRI) in Salla disease, a free sialic acid storage disorder. Neuropediatrics 1994, 25:238-244.
79. Sonninen P., Autti T., Varho T., et al. Brain involvement in Salla disease. Am J Neuroradiol 1999, 20:433-443.
80. Mochel F., Yang B., Barritault J., et al. Free sialic acid storage disease without sialuria. Ann Neurol 2009, 65:753-757.
81. Mochel F., Sedel F., Vanderver A., et al. Cerebellar ataxia with elevated cerebrospinal free sialic acid (CAFSA). Brain 2009, 132:801-809.
82. Suhonen-Polvi H., Varho T., Metsähonkala L., et al. Increased brain glucose utilization in Salla disease (free sialic acid storage disorder). J Nucl Med 1999, 40:12-18.
83. Chinnery P.F. Mitochondrial disorders overview. 2000 Jun 8 [Updated 2010 Sep 16]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1224, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
84. DiMauro S., Hirano M. MELAS. 2001 Feb 27 [Updated 2010 Oct 14]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1233/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
85. Ito H., Mori K., Kagami S. Neuroimaging of stroke-like episodes in MELAS. Brain Dev 2011, 33:283-288.
86. Chu B.C., Terae S., Takahashi C., et al. MRI of the brain in the Kearns-Sayre syndrome: Report of four cases and a review. Neuroradiology 1999, 41:759-764.
87. Serrano M., Garcia-Silva M.T., Martin-Hernandez E., et al. Kearns-Sayre syndrome: Cerebral folate deficiency, MRI findings and new cerebrospinal fluid biochemical features. Mitochondrion 2010, 10:429-432.
88. Duning T., Deppe M., Keller S., et al. Diffusion tensor imaging in a case of Kearns-Sayre syndrome: Striking brainstem involvement as a possible cause of oculomotor symptoms. J Neurol Sci 2009, 281:110-112.
89. Finsterer J. Leigh and Leigh-Like syndrome in children and adults. Pediatr Neurol 2008, 39:223-235.
90. Nagashima T., Mori M., Katayama K., et al. Adult Leigh syndrome with mitochondrial DNA mutation at 8993. Acta Neuropathol 1999, 97:416-422.
91. Goldenberg P.C., Steiner R.D., Merkens L.S., et al. Remarkable improvement in adult Leigh syndrome with partial cytochrome c oxidase deficiency. Neurology 2003, 60:865-868.
92. Maldergem L.V., Trijbels F., DiMauro S., et al. Coenzyme Q-Responsive Leigh's encephalopathy in two sisters. Ann Neurol 2002, 52:750-754.
93. McKelvie P., Infeld B., Marotta R., et al. Late-adult onset Leigh syndrome. J Clin Neurosci 2012, 19:195-202.
94. Patel K.P., O'Brien T.W., Subramony S.H., et al. The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients. Mol Genet Metab 2012, 106:385-394.
95. Barkovich A.J., Good W.V., Koch T.K., et al. Mitochondrial disorders: Analysis of their clinical and imaging characteristics. Am J Neuroradiol 1993, 14:1119-1137.
96. Kendall B.E. Disorders of lysosomes, peroxisomes, and mitochondria. Am J Neuroradiol 1992, 13:621-653.
97. Chuang C.S., Lo M.C., Lee K.W., et al. Magnetic resonance spectroscopy study in basal ganglia of patients with myoclonic epilepsy with ragged-red fibers. Neurol India 2007, 55:385-387.
98. Ito S., Shirai W., Asahina M., et al. Clinical and brain MR imaging features focusing on the brain stem and cerebellum in patients with myoclonic epilepsy with ragged-red fibers due to mitochondrial A8344G mutation. Am J Neuroradiol 2008, 29:392-395.
99. deBruyn J., Chan A., Bhargava R., et al. Liver failure in mitochondrial DNA depletion syndrome: The importance of serial neuroimaging in liver transplantation evaluation. J Pediatr Gastroenterol Nutr 2007, 45:252-256.
100. Merkle A.N., Nascene D.R., McKinney A.M. MR imaging findings in the reticular formation in siblings with MPV17-related mitochondrial depletion syndrome. Am J Neuroradiol 2012, 33:E34-E35.
101. Ruegger C.M., Lindner M., Ballhausen D., et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. J Inherit Metab Dis 2013, [Epub ahead of print].
102. Saheki T., Inoue K., Tushima A., et al. Citrin deficiency and current treatment concepts. Mol Genet Metab 2010, 100(suppl):S59-S64.
103. Takanashi J., Barkovich A.J., Cheng S.F., et al. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. Am J Neuroradiol 2003, 24:390-393.
104. McKinney A.M., Lohman B.D., Sarikaya B., et al. Acute hepatic encephalopathy: Diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. Am J Neuroradiol 2010, 31:1471-1479.
105. McKinney A.M., Teksam M., Felice R., et al. Diffusion-weighted imaging in the setting of diffuse cortical laminar necrosis and hypoxic-ischemic encephalopathy. Am J Neuroradiol 2005, 25:1659-1665.
106. 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab 2008, 95:21-30.
107. 1H MR spectroscopy showing elevation of brain guanidinoacetate in argininosuccinate lyase deficiency. Mol Genet Metab 2006, 88:100-102.
108. Gropman A.L., Gertz B., Shattuck K., et al. Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency. Am J Neuroradiol 2010, 31:1719-1723.
109. Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab 2010, 100(suppl):S20-S30.
110. Kasim S., Moo L.R., Zschocke J., et al. Phenylketonuria presenting in adulthood as progressive spastic paraparesis with dementia. J Neurol Neurosurg Psychiatry 2001, 71:795-797.
111. Jousserand G., Antoine J.C., Camdessanche J.P. Musty odour, mental retardation, and spastic paraplegia revealing phenylketonuria in adulthood. J Neurol 2010, 257:302-304.
112. Kono K., Okana Y., Nakayama, et al. Diffusion-weighted MR Imaging in patients with phenylketonuria: Relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology 2005, 236:630-636.
113. 1H MRS) study. J Inherit Metab Dis 2007, 30:209-216.
114. Anderson P.J., Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab 2010, 99(suppl 1):S3-S9.
115. Christ S.E., Huijbregts S.C.J., de Sonneville L.M.J., et al. Executive function in early-treated phenylketonuria: Profile and underlying mechanisms. Mol Genet Metab 2010, 99(suppl 1):S22-S32.
116. Christ S.E., Moffitt A.J., Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol Genet Metab 2010, 99(suppl 1):S33-S40.
117. Rawal S., Faghfoury H., Krings T. MRI findings in adult maple syrup urine disease exacerbation. Can J Neurol Sci 2013, 40:259-262.
118. Sutter R., Killer H.E., Bilz S., et al. Cerebral edema and intracranial hypertension in an adult with maple syrup urine disease. Eur J Neurol 2009, 16:e45-e46.
119. Schönberger S., Schweiger B., Schwahn B., et al. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. l Genet Metab 2004, 82:69-75.
120. Bischof F., Nagele T., Wanders R.J.A., et al. 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency in an adult with leukoencephalopathy. Ann Neurol 2004, 56:727-730.
121. Reimao S., Morgado C., Almeida I.T., et al. 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: Initial presentation in a young adult. J Inherit Metab Dis 2009, 32(suppl 1):S49-S52.
122. Van der Knaap M.S., Bakker H.D., Valk J. MR imaging and proton spectroscopy in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency. Am J Neuroradiol 1998, 19:378-382.
123. Yalcinkaya C., Dincer A., Gunduz E., et al. MRI and MRS in HMG-CoA lyase deficiency. Pediatr Neurol 1999, 20:375-380.
124. Sonmez G., Mutlu H., Ozturk E., et al. Magnetic resonance imaging findings of adult-onset glutaric aciduria type I. Acta Radiol 2007, 48:557-559.
125. Bahr O., Mader I., Zschocke J., et al. Adult onset glutaric aciduria type I presenting with a leukoencephalopathy. Neurology 2002, 59:1802-1804.
126. Rosenbohm A., Sussmuth S.D., Kassubek J., et al. Novel ETFDH mutation and imaging findings in an adult with glutaric aciduria type II. Muscle Nerve 2013, [Epub ahead of print].
127. Manoli I., Venditti C.P. Methylmalonic acidemia. 2005 Aug 16 [Updated 2010 Sep 28]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
128. Baumgarter E.R., Viardot C. Long-term follow-up of 77 patients with isolated methylmalonic acidaemia. J Inherit Metab Dis 1995, 18:138-142.
129. Korf B., Wallman J.K., Levy H.L. Bilateral lucency of the globus pallidus complicating methylmalonic academia. Ann Neurol 1986, 20:364-366.
130. Michel S.J., Given C.A., Robertson W.C. Imaging of the brain, including diffusion-weighted imaging in methylmalonic acidemia. Pediatr Radiol 2004, 34:580-582.
131. Brismar J., Ozand P.T. CT and MR of the brain in the diagnosis of organic acidemias. Experiences from 107 patients. Brain Dev 1994, 16(suppl):104-124.
132. Heidenreich R., Natowicz M., Hainline B.E., et al. Acute extrapyramidal syndrome in methylmalonic acidemia: "Metabolic stroke" involving the globus pallidus. J Pediatr 1988, 113:1022-1027.
133. Yeşildaǧ A., Ayata A., Baykal B., et al. Magnetic resonance imaging and diffusion-weighted imaging in methylmalonic acidemia. Acta Radiol 2005, 46:101-103.
134. Burlina A.P., Manara R., Calderone M., et al. Diffusion-weighted imaging in the assessment of neurological damage in patients with methylmalonic aciduria. J Inherit Metab Dis 2003, 26:417-422.
135. Harting I., Seitz A., Geb S., et al. Looking beyond the basal ganglia: The spectrum of MRI changes in methylmalonic acidaemia. J Inherit Metab Dis 2008, 31:368-378.
136. Radmanesh A., Zaman T., Ghanaati H., et al. Methylmalonic acidemia: Brain imaging findings in 52 children and a review of the literature. Pediatr Radiol 2008, 38:1054-1061.
137. Trinh B.C., Melhem E.R., Barker P.B. Multi-slice proton MR spectroscopy and diffusion-weighted imaging in methylmalonic acidemia: Report of two cases and review of the literature. Am J Neuroradiol 2001, 22:831-833.
138. Yorifuji T., Kawai M., Muroi J., et al. Unexpectedly high prevalence of the mild form of propionic acidemia in Japan: Presence of a common mutation and possible clinical implications. Hum Genet 2002, 111:161-165.
139. Sethi K.D., Ray R., Roesel R.A., et al. Adult-onset chorea and dementia with propionic acidemia. Neurology 1989, 39:1343-1345.
140. Williams Z.R., Hurley P.E., Altiparmak U.E., et al. Late onset optic neuropathy in methylmalonic and propionic acidemia. Am J Ophthalmol 2009, 147:929-933.
141. Bergman A.J., Van der Knaap M.S., Smeitink J.A., et al. Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: Clinical and biochemical considerations. Pediatr Res 1996, 40:404-409.
142. Chemelli A.P., Schocke M., Sperl W., et al. Magnetic resonance spectroscopy (MRS) in five patients with treated propionic acidemia. J Magn Reson Imaging 2000, 11:596-600.
143. Brismar J., Ozand P.T. CT and MR of the brain in disorders of the propionate and methylmalonate metabolism. Am J Neuroradiol 1994, 15:1459-1473.
144. Wortmann S.B., Kremer B.H., Graham A., et al. 3-Methylglutaconic aciduria type I redefined: A syndrome with late-onset leukoencephalopathy. Neurology 2010, 75:1079-1083.
145. Eriguchi M., Mizuta H., Kurohara K., et al. 3-Methylglutaconic aciduria type I causes leukoencephalopathy of adult onset. Neurology 2006, 67:1895-1896.
146. Steenweg M.E., Salomons G.S., Yapici Z., et al. l-2-Hydroxyglutaric aciduria: Pattern of MR imaging abnormalities in 56 patients. Radiology 2009, 251:856-865.
147. Topcu M., Aydin O.F., Yalcinkaya C., et al. l-2-Hydroxyglutaric aciduria: A report of 29 patients. Turk J Pediatr 2005, 47:1-7.
148. Gorospe J.R. Alexander disease. 2002 Nov 15 [Updated 2010 Apr 22]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
149. Prust B.A., Wang J., Morizono H., et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology 2011, 77:1287-1294.
150. Pareyson D., Fancellu R., Mariotti C., et al. Adult-onset Alexander disease: A series of eleven unrelated cases with review of the literature. Brain 2008, 131:2321-2331.
151. Balbi P., Salvini S., Fundaro C., et al. The clinical spectrum of late-onset Alexander disease: A systematic literature review. J Neurol 2010, 257:1955-1962.
152. Farina L., Pareyson D., Minati L., et al. Can MR imaging diagnose adult-onset Alexander disease?. Am J Neuroradiol 2008, 29:1190-1196.
153. Schmidt H., Kretzschmara B., Lingor P., et al. Acute onset of adult Alexander disease. J Neurol Sci 2013, 331:152-154.
154. Schmidt S., Wattjes M.P., Gerding W.M., et al. Late onset Alexander's disease presenting as cerebellar ataxia associated with a novel mutation in the GFAP gene. J Neurol 2011, 258:938-940.
155. Hobson G.M., Kamholz J. PLP1-related disorders. 1999 Jun 15 [Updated 2013 Feb 28]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
156. Sasaki A., Miyanaga K., Ototsuji M., et al. Two autopsy cases with Pelizaeus-Merzbacher disease phenotype of adult onset, without mutation of proteolipid protein gene. Acta Neuropathol 2000, 99:7-13.
157. Osaka H., Koizume S., Aoyama H., et al. Mild phenotype in Pelizaeus-Merzbacher disease caused by a PLP1-specific mutation. Brain Dev 2010, 32:703-707.
158. Hübner C.A., Senning A., Orth U., et al. Mild Pelizaeus-Merzbacher disease caused by a point mutation affecting correct splicing of PLP1 mRNA. Neuroscience 2005, 132:697-701.
159. Takanashi J., Inoue K., Tomita M., et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002, 58:237-241.
160. Olivarez L., Caggana M., Pass K.A., et al. Estimate of the frequency of Wilson's disease in the US Caucasian population: A mutation analysis approach. Ann Hum Genet 2001, 65:459-463.
161. Weiss K.H. Wilson disease. 1999 Oct 22 [Updated 2013 May 16]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1512/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
162. Sinha S., Taly A.B., Ravishankar S., et al. Wilson's disease: Cranial MRI observations and clinical correlation. Neuroradiology 2006, 48:613-621.
163. King A.D., Walshe J.M., Kendall B.E., et al. Cranial MR imaging in Wilson's disease. Am J Roentgenol 1996, 167:1579-1584.
164. Sinha S., Taly A.B., Prashanth L.K., et al. Sequential MRI changes in Wilson's disease with de-coppering therapy: A study of 50 patients. Br J Radiol 2007, 80:744-749.
165. Sener R.N. Diffusion MRI findings in Wilson's disease. Comput Med Imaging Graph 2003, 27:17-21.
166. Lucato L.T., Otaduy M.C., Barbosa E.R., et al. Proton MR Spectroscopy in Wilson disease: Analysis of 36 cases. Am J Neuroradiol 2005, 26:1066-1071.
167. Jadav R., Saini J., Sinha S., et al. Diffusion tensor imaging (DTI) and its clinical correlates in drug naïve Wilson's disease. Metab Brain Dis 2013, 28:455-462.
168. Zheng Z., Diamond M.I. Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci 2012, 107:189-214.
169. Warby S.C., Graham R.K., Hayden M.R. Huntington disease. 1998 Oct 23 [Updated 2010 Apr 22]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
170. Duff K., Paulsen J., Mills J., et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010, 75:500-507.
171. Aylward E.H., Sparks B.F., Field K.M., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
172. Tabrizi S.J., Scahill R.I., Owen G., et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol 2013, 12:637-649.
173. Georgiou-Karistianis N., Scahill R., Tabrizi S.J., et al. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev 2013, 37:480-490.
174. Stoffers D., Sheldon S., Kuperman J.M., et al. Contrasting gray and white matter changes in preclinical Huntington disease: An MRI study. Neurology 2010, 74:1208-1216.
175. Unschuld P.G., Edden R.A., Carass A., et al. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord 2012, 27:895-902.
176. Ginestroni A., Battaglini M., Diciotti S., et al. Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease. Am J Neuroradiol 2010, 31:1807-1812.
177. Reading S.A., Yassa M.A., Bakker A., et al. Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study. Psychiatry Res 2005, 140:55-62.
178. Rosas H.D., Tuch D.S., Hevelone N.D., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006, 21:1317-1325.
179. Weaver K.E., Richards T.L., Liang O., et al. Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol 2009, 216:525-529.
180. Magnotta V.A., Kim J., Koscik T., et al. Diffusion tensor imaging in preclinical Huntington's disease. Brain Imaging Behav 2009, 3:77-84.
181. Rosas H.D., Lee S.Y., Bender A.C., et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical "disconnection". Neuroimage 2010, 49:2995-3004.
182. Sritharan A., Egan G.F., Johnston L., et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry 2010, 81:257-262.
183. Bohanna I., Georgiou-Karistianis N., Sritharan A., et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav 2011, 5:171-180.
184. Paulsen J.S. Functional imaging in Huntington's disease. Exp Neurol 2009, 216:272-277.
185. Ciarmiello A., Giovacchini G., Orobello S., et al. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging 2012, 39:1030-1036.
186. Enzi B., Edel M.A., Lissek S., et al. Altered ventral striatal activation during reward and punishment processing in premanifest Huntington's disease: A functional magnetic resonance study. Exp Neurol 2012, 235:256-264.
187. Wolf R.C., Grön G., Sambataro F., et al. Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Hum Brain Mapp 2012, 33:2161-2173.
188. Wolf R.C., Sambataro F., Vasic N., et al. Default-mode network changes in preclinical Huntington's disease. Exp Neurol 2012, 237:191-198.
189. Georgiou-Karistianis N., Poudel G.R., Domínguez D.J.F., et al. Functional and connectivity changes during working memory in Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. Brain Cogn 2013, 83:80-91.
190. Georgiou-Karistianis N., Stout J.C., JF Domínguez D., et al. Functional magnetic resonance imaging of working memory in Huntington's disease: Cross-sectional data from the IMAGE-HD study. Hum Brain Mapp 2013, [Epub ahead of print]. 10.1002/hbm.22296.
191. Georgiou-Karistianis N., Gray M.A., JF Domínguez D., et al. Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: The IMAGE-HD study. Neurobiol Dis 2013, 51:82-92.
192. Gray M.A., Egan G.F., Ando A., et al. Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: The IMAGE-HD study. Exp Neurol 2013, 239:218-228.
193. Gregory A., Polster B.J., Hayflick S.J. Clinical and genetic delineation of Neurodegeneration with brain iron accumulation. J Med Genet 2009, 46:73-80.
194. Kruer M.C., Boddaert N., Schneider S.A., et al. Neuroimaging features of Neurodegeneration with brain iron accumulation. Am J Neuroradiol 2012, 33:407-414.
195. Gregory A., Hayflick S.J. Pantothenate kinase-associated neurodegeneration. 2002 Aug 13 [Updated 2013 Jan 31]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1490/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
196. Chinnery P.F. Neuroferritinopathy. 2005 Apr 25 [Updated 2010 Dec 23]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1141/, R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
197. Crompton D.E., Chinnery P.F., Fey C., et al. Neuroferritinopathy: A window on the role of iron in neurodegeneration. Blood Cells Mol Dis 2002, 29:522-531.
198. Nittis T., Gitlin J. The copper-iron connection: Hereditary aceruloplasminemia. Semin Hematol 2002, 39:282-289.
199. Miyajima H., Takahashi Y., Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003, 16:205-213.
200. Williams D.R., Hadeed A., al-Din A.S.N., et al. Kufor Rakeb disease: Autosomal recessive, levodopa-responsive Parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Movement Disorders 2005, 20:1264-1271.
201. Brüggemann N., Hagenah J., Reetz K., et al. Recessively inherited parkinsonism: Effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010, 67:1357-1363.
202. Schneider S.A., Bhatia K.P. Dystonia in the Woodhouse Sakati syndrome: A new family and literature review. Mov Disord 2008, 23:592-596.
203. Al-Semari A., Bohlega S. Autosomal-recessive syndrome with alopecia, hypogonadism, progressive extra-pyramidal disorder, white matter disease, sensory neural deafness, diabetes mellitus, and low IGF1. Am J Med Genet 2007, 143A:149-160.
204. Hartig M.B., Iuso A., Haack T., et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 2011, 89:543-550.
205. Hogarth P., Gregory A., Kruer M.C., et al. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013, 80:268-275.
206. Kimura Y., Sato N., Sugai K., et al. MRI, MR spectroscopy, and diffusion tensor imaging findings in patient with static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). Brain Dev 2013, 35:458-461.
207. Van Der Knaap M.S., Barth P.G., Stroink H., et al. Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol 1995, 37:324-334.
208. Brockmann K., Finsterbusch J., Terwey B., et al. Megalencephalic leucoencephalopathy with subcortical cysts in an adult: Quantitative proton MR spectroscopy and diffusion tensor MRI. Neuroradiology 2003, 45:137-142.
209. Tu Y.F., Chen C.Y., Huang C.C., et al. Vacuolating megalencephalic leukoencephalopathy with mild clinical course validated by diffusion tensor imaging and MR spectroscopy. Am J Neuroradiol 2004, 25:1041-1045.
210. Singhal B.S., Gursahani R.D., Udani V.P., et al. Megalencephalic leukodystrophy in an Asian Indian ethnic group. Pediatr Neurol 1996, 14:291-296.
211. Topcu M., Saatci I., Topcuoglu M.A., et al. Megalencephay and leukodystrophy with mild clinical course: A report on 12 new cases. Brain Dev 1998, 20:142-153.
212. van der Knaap M.S., Lai V., Köhler W., et al. Megalencephalic leukoencephalopathy with cysts without MLC1 defect. Ann Neurol 2010, 67:834-837.
213. van der Knaap M.S., Barth P.G., Gabreëls F.J., et al. A new leukoencephalopathy with vanishing white matter. Neurology 1997, 48:845-855.
214. van der Knaap M.S., Kamphorst W., Barth P.G., et al. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998, 51:540-547.
215. van der Knaap M.S., Pronk J.C., Scheper G.C. Vanishing white matter disease. Lancet Neurol 2006, 5:413-423.
216. Bugiani M., Boor I., van Kollenburg B., et al. Defective glial maturation in vanishing white matter disease. J Neuropathol Exp Neurol 2011, 70:69-82.
217. van der Lei H.D., Steenweg M.E., Bugiani M., et al. Restricted diffusion in vanishing white matter. Arch Neurol 2012, 69:723-727.
218. Schiffmann R., Fogli A., Van der Knaap M.S., Boespflug-Tanguy O. Childhood ataxia with central nervous system hypomyelination/vanishing white matter. 2003 Feb 20 [updated 2012 Aug 09]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle. R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
219. Timmons M., Tsokos M., Abu Asab M., et al. Peripheral and central hypomyelination with hypogonadotropic hypogonadism and hypodontia. Neurology 2006, 67:2066-2069.
220. Vanderver A., Tonduti D., Bernard G., et al. More than hypomyelination in Pol-III disorder. J Neuropathol Exp Neurol 2013, 72:67-75.
221. Outteryck O., Devos D., Jissendi P., et al. 4H syndrome: A rare cause of leukodystrophy. J Neurol 2010, 257:1759-1761.
222. Sobrido M.J., Coppola G., Oliveira J., et al. Primary familial brain calcification. 2004 Apr 18 [Updated 2013 Jun 27]. GeneReviews™ [Internet] 1993-2013, University of Washington, Seattle. R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
223. Manyam B.V., Walters A.S., Narla K.R. Bilateral striopallidodentate calcinosis: Clinical characteristics of patients seen in a registry. Mov Disord 2001, 16:258-264.
224. Tong K.A., Ashwal S., Obenaus A., et al. Susceptibility-weighted MR imaging: A review of clinical applications in children. Am J Neuroradiol 2008, 29:9-17.
225. Koob M., Laugel V., Durand M., et al. Neuroimaging in Cockayne syndrome. Am J Neuroradiol 2010, 31:1623-1630.
226. Rapin I., Weidenheim K., Lindenbaum Y., et al. Cockayne syndrome in adults: Review with clinical and pathologic study of a new case. J Child Neurol 2006, 21:991-1006.
227. Nance M.A., Berry S.A. Cockayne syndrome: Review of 140 cases. Am J Med Genet 1992, 42:68-84.